NCT03448341 (DASRT) is a clinical trial in Cancer of Oropharynx, sponsored by Azienda Ospedaliero, Universitaria Pisana.

Who is sponsoring NCT03448341?

NCT03448341 is sponsored by Azienda Ospedaliero, Universitaria Pisana.

What condition does NCT03448341 study?

NCT03448341 studies Cancer of Oropharynx, Cancer of Nasopharynx.

Is NCT03448341 still recruiting?

NCT03448341 is currently completed. Last updated 15 September 2022.

Last reviewed 2022-09-15 · How we verify

NCT03448341: DASRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dysphagia Assessment After Swallowing Sparing RadioTherapy

Completed Last updated 15 September 2022

What this trial tests

trial in Cancer of Oropharynx in 74 participants. Completed in 31 January 2022.

Timeline

16 July 2016

Primary endpoint
1 May 2020

31 January 2022

Quick facts

Lead sponsor	Azienda Ospedaliero, Universitaria Pisana
Status	Completed
Study type	OBSERVATIONAL
Enrollment	74
Start date	16 July 2016
Primary completion	1 May 2020
Estimated completion	31 January 2022
Sites	1 location across Italy

Conditions studied

Cancer of Oropharynx — all drugs for Cancer of Oropharynx →
Cancer of Nasopharynx — all drugs for Cancer of Nasopharynx →

Sponsor

Azienda Ospedaliero, Universitaria Pisana — full company profile →

Who can join

Adults 18 to 80, any sex, with Cancer of Oropharynx or Cancer of Nasopharynx. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To prospectively assess post-radiation late dysphagia by using MDADI questionnaire (deglutition-related quality of life) and objective instrumental assessment by means of Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and Videofluoroscopy (VFS) in patients affected by nasopharynx and oropharynx cancers candidates to radiochemotherapy. Radiotherapy is delivered by using Intensity and Modulated Technique (IMRT) with a planning dose optimization to the swallowing related structures (SWOARs-sparing IMRT). The primary aim is to assess the variations of MDADI, FEES and VFS from baseline to 6 and 12 months after treatment. The secondary aim is to correlate clinical and instrumental results as well as radiation dose received by the different swallowing related structures (SWOARs) to the variations of clinical (MDADI) and instrumental (FEES and VFS) scores.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Patient-Reported Outcomes After Swallowing (SWOARs)-Sparing IMRT in Head and Neck Cancers: Primary Results from a Prospective Study Endorsed by the Head and Neck Study Group (HNSG) of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Ursino S, Calistri E, De Felice F, Bonomo P, et al · · 2023 · cited 6× · PMID 35587295 · DOI 10.1007/s00455-022-10434-4

Verify or expand the search:

Other Azienda Ospedaliero, Universitaria Pisana trials

Trials by the same sponsor.

NCT07512453 — Study in Patients With Osteoporosis and Fragility Fractures to Estimate the Extent and Impact of Delayed Administration · not yet recruiting
NCT06333132 — Deciphering the Role of Incretin Hormones in Weight Loss-induced Remission of Type 2 Diabetes (DIABeat) · NA · unknown
NCT07250607 — Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications · active not recruiting
NCT07132086 — Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting · completed
NCT06876948 — NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencep · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03448341 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda Ospedaliero, Universitaria Pisana
Last refreshed: 15 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03448341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing